- Home
- PANL vs DSGN Comparison
PANL vs DSGN Comparison
Compare PANL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PANL
- DSGN
- Stock Information
- Founded
- PANL 1996
- DSGN 2017
- Country
- PANL United States
- DSGN United States
- Employees
- PANL N/A
- DSGN N/A
- Industry
- PANL Marine Transportation
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- PANL Consumer Discretionary
- DSGN Health Care
- Exchange
- PANL Nasdaq
- DSGN Nasdaq
- Market Cap
- PANL 369.0M
- DSGN 348.2M
- IPO Year
- PANL N/A
- DSGN 2021
- Fundamental
- Price
- PANL $5.56
- DSGN $4.87
- Analyst Decision
- PANL Strong Buy
- DSGN Hold
- Analyst Count
- PANL 1
- DSGN 3
- Target Price
- PANL N/A
- DSGN $7.00
- AVG Volume (30 Days)
- PANL 250.7K
- DSGN 220.6K
- Earning Date
- PANL 03-12-2025
- DSGN 03-18-2025
- Dividend Yield
- PANL 7.19%
- DSGN N/A
- EPS Growth
- PANL N/A
- DSGN N/A
- EPS
- PANL 0.47
- DSGN N/A
- Revenue
- PANL $521,238,386.00
- DSGN N/A
- Revenue This Year
- PANL $8.04
- DSGN N/A
- Revenue Next Year
- PANL $13.05
- DSGN N/A
- P/E Ratio
- PANL $11.75
- DSGN N/A
- Revenue Growth
- PANL 5.23
- DSGN N/A
- 52 Week Low
- PANL $4.82
- DSGN $2.25
- 52 Week High
- PANL $9.53
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- PANL 52.43
- DSGN 42.19
- Support Level
- PANL $5.56
- DSGN $3.71
- Resistance Level
- PANL $5.88
- DSGN $6.81
- Average True Range (ATR)
- PANL 0.20
- DSGN 0.50
- MACD
- PANL 0.06
- DSGN -0.10
- Stochastic Oscillator
- PANL 61.90
- DSGN 37.42
About PANL Pangaea Logistics Solutions Ltd.
Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk transportation services. It transports drybulk cargos including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The firm's services include cargo loading, cargo discharge, vessel chartering, voyage planning and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.